Albireo to Announce Topline Results from PEDFIC 1 Phase 3 Trial of Odevixibat on September 8, 2020

Rhea-AI Summary

Albireo Pharma (ALBO) announced that it will reveal topline results from the PEDFIC 1 Phase 3 trial for its lead candidate, odevixibat, on September 8, 2020. This trial evaluates the efficacy and safety of odevixibat for treating progressive familial intrahepatic cholestasis (PFIC). Following the announcement, company management will host a conference call and live audio webcast to discuss the results at 8:30 a.m. EDT. Odevixibat is also in development for biliary atresia and a Phase 3 trial for Alagille syndrome is being planned.

Positive

• The upcoming announcement of topline results from the Phase 3 PEDFIC 1 trial could signal significant progress for odevixibat.
• Odevixibat is being developed for multiple orphan pediatric liver diseases, indicating a broad market potential.

Negative

• None.

BOSTON, Sept. 07, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that topline results from the PEDFIC 1 Phase 3 clinical trial evaluating the efficacy and safety of lead candidate odevixibat for the treatment of progressive familial intrahepatic cholestasis (PFIC) will be announced September 8, 2020. Company management will host a conference call and live audio webcast at 8:30 a.m. EDT to review the results.

To access the live conference call and webcast tomorrow, September 8, 2020, at 8:30 a.m. EDT, please dial 877-407-0792 (domestic) or 201-689-8263 (international) and provide the access code 13709929. The live audio webcast of the presentation will be accessible from the Media & Investors page of Albireo’s website, ir.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo’s website for at least two weeks following the event.

About Albireo
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo’s lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in progressive familial intrahepatic cholestasis (PFIC) and biliary atresia, with a third Phase 3 trial being planned in Alagille syndrome.

Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Mass., and its key operating subsidiary is located in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit www.albireopharma.com.

Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578         

Media Contact:
Colleen Alabiso, Albireo Pharma, colleen.alabiso@albireopharma.com
Claire LaCagnina, 6 Degrees, 315-765-1462, clacagnina@6degreespr.com

FAQ

What are the topline results of the PEDFIC 1 trial for ALBO?

The topline results for the PEDFIC 1 trial will be announced on September 8, 2020.

What conditions is odevixibat targeting?

Odevixibat is targeting progressive familial intrahepatic cholestasis and biliary atresia, with future plans for Alagille syndrome.

When is the conference call for ALBO's trial results?

The conference call will take place on September 8, 2020, at 8:30 a.m. EDT.

How can I access the live webcast for the odevixibat trial results?

The live audio webcast can be accessed via Albireo's website and requires registration at least 15 minutes prior to the event.